Drusen volume as a predictor of disease progression in patients with late age-related macular degeneration in the fellow eye

Investigative Ophthalmology and Visual Science

Volumn 57, Issue 4, 2016, Pages 1839-1846

  Abdelfattah, Nizar Saleh ^a,b   Zhang, Hongyang ^a,b,c   Boyer, David S ^d   Rosenfeld, Philip J ^e   Feuer, William J ^e   Gregori, Giovanni ^e   Sadda, Srinivas R ^a,b  

^a DOHENY EYE INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Choroidal neovascularization; Drusen volume; Geographic atrophy; Macular degeneration; Optical coherence tomography; Retinal drusen; Wet macular degeneration

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; B SCAN; CONTROLLED STUDY; DISEASE COURSE; DRUSEN VOLUME; FEMALE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK FACTOR; VISUAL SYSTEM PARAMETERS; COMBINATION DRUG THERAPY; COMPLICATION; DOSE RESPONSE; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; IMAGE PROCESSING; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; MIDDLE AGED; PROCEDURES; PROGNOSIS; RETINAL DRUSEN; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PROGNOSIS; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL DRUSEN; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84963732262     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.15-18572     Document Type: Article

References (29)

1. Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol. 2012; 96: 614-618.
2. Rein DB, Wittenborn JS, Zhang X, Honeycutt AA, Lesesne SB, Saaddine J. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol. 2009; 127: 533-540.
3. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol. 1995; 39: 367-374.
4. Kawasaki R, Yasuda M, Song SJ, et al. The prevalence of agerelated macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology. 2010; 117: 921-927.
5. Krishnan T, Ravindran RD, Murthy GVS, et al. Prevalence of early and late age-related macular degeneration in India: the INDEYE study. Invest Ophthalmol Vis Sci. 2010; 51: 701-707.
6. Klein R, Chou C-F, Klein BEK, Zhang X, Meuer SM, Saaddine JB. Prevalence of age-related macular degeneration in the US population. Arch Ophthalmol. 2011; 129: 75-80.
7. Bressler SB, Maguire MG, Bressler NM, Fine SL. Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. The Macular Photocoagulation Study Group. Arch Ophthalmol. 1990; 108: 1442-1447.
8. Pauleikhoff D, Barondes MJ, Minassian D, Chisholm IH, Bird AC. Drusen as risk factors in age-related macular disease. Am J Ophthalmol. 1990; 109: 38-43.
9. Ferris FL, Davis MD, Clemons TE, et al. A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol. 2005; 123: 1570-1574
10. Klein R, Klein BEK, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2007; 114: 253-262.
11. Bartlett H, Eperjesi F. Use of fundus imaging in quantification of age-related macular change. Surv Ophthalmol. 2007; 52: 655-671.
12. Cukras C, Agrón E, Klein ML, et al. Natural history of drusenoid pigment epithelial detachment in age-related macular degeneration: Age-Related Eye Disease Study Report No. 28. Ophthalmology. 2010; 117: 489-499.
13. Smith RT, Chan JK, Nagasaki T, Sparrow JR, Barbazetto I. A method of drusen measurement based on reconstruction of fundus background reflectance. Br J Ophthalmol. 2005; 89: 87-91.
14. Gregori G, Wang F, Rosenfeld PJ, et al. Spectral domain optical coherence tomography imaging of drusen in nonexudative age-related macular degeneration. Ophthalmology. 2011; 118: 1373-1379.
15. Yehoshua Z, Wang F, Rosenfeld PJ, Penha FM, Feuer WJ, Gregori G. Natural history of drusen morphology in age-related macular degeneration using spectral domain optical coherence tomography. Ophthalmology. 2011; 118: 2434-2441.
16. Gregori G, Yehoshua Z, Garcia Filho CA, et al. Change in drusen area over time compared using spectral-domain optical coherence tomography and color fundus imaging. Invest Ophthalmol Vis Sci. 2014; 55: 7662-7668.
17. Nittala MG, Ruiz-Garcia H, Sadda SR. Accuracy and reproducibility of automated drusen segmentation in eyes with nonneovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2012; 53: 8319-8324.
18. Diniz B, Rodger DC, Chavali VR, et al. Drusen and RPE atrophy automated quantification by optical coherence tomography in an elderly population. Eye (Lond). 2015; 29: 272-279.
19. Chavali V, Diniz B, Huang J, Ying G-S, Sadda S, Stambolian D. Association of OCT-derived drusen measurements with AMDassociated genotypic SNPs in the Amish population. J Clin Med. 2015; 4: 304-317.
20. Garcia Filho CA, Yehoshua Z, Gregori G, et al. Change in drusen volume as a novel clinical trial endpoint for the study of complement inhibition in age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina. 2014; 45: 18-31.
21. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977; 33: 159-174.
22. Chew EY, Clemons TE, Agrón E, et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmol. 2014; 132: 272-277.
23. Ouyang Y, Heussen FM, Hariri A, Keane PA, Sadda SR. Optical coherence tomography-based observation of the natural history of drusenoid lesion in eyes with dry age-related macular degeneration. Ophthalmology. 2013; 120: 2656-2665.
24. Chiu SJ, Izatt JA, O'Connell RV, Winter KP, Toth CA, Farsiu S. Validated automatic segmentation of AMD pathology including drusen and geographic atrophy in SD-OCT images. Invest Ophthalmol Vis Sci. 2012; 53: 53-61.
25. Schlanitz FG, Sacu S, Baumann B, et al. Identification of drusen characteristics in age-related macular degeneration by polarizationsensitive optical coherence tomography. Am J Ophthalmol. 2015; 160: 335-344.
26. Sandhu SS, Talks SJ. Correlation of optical coherence tomography, with or without additional colour fundus photography, with stereo fundus fluorescein angiography in diagnosing choroidal neovascular membranes. Br J Ophthalmol. 2005; 89: 967-970.
27. Do DV, Gower EW, Cassard SD, et al. Detection of new-onset choroidal neovascularization using optical coherence tomography: the AMD DOC Study. Ophthalmology. 2012; 119: 771-778.
28. Lujan BJ, Rosenfeld PJ, Gregori G, et al. Spectral domain optical coherence tomographic imaging of geographic atrophy. Ophthalmic Surg Lasers Imaging. 2009; 40: 96-101.
29. Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, et al. Comparison of geographic atrophy growth rates using different imaging modalities in the COMPLETE Study. Ophthalmic Surg Lasers Imaging Retina. 2015; 46: 413-422.